Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Scandinavian Journal of Rheumatology|November 2, 2021
Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational studyT Rusman, M T Nurmohamed, S Hoekstra, et al.
Annals of the Rheumatic Diseases|March 24, 2012
Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritisR Klaasen, M M J Herenius, C A Wijbrandts, et al.
Annals of the Rheumatic Diseases|November 19, 2009
Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritisI C van Eijk, M E Tushuizen, A Sturk, et al.
Biologics : Targets & Therapy|December 5, 2018
The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitisS C Heslinga, T C Konings, I E van der Horst-Bruinsma, et al.
Thrombosis and Haemostasis|January 23, 1992
Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoidJ A Hoek, M T Nurmohamed, K J Hamelynck, et al.
Plos One|October 10, 2018
Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-upE H Vogelzang, R C F Hebing, M T Nurmohamed, et al.
Annals of the Rheumatic Diseases|May 1, 2009
Ankylosing spondylitis: a risk factor for myocardial infarction?M J L Peters, I Visman, M M J Nielen, et al.
Annals of the Rheumatic Diseases|December 24, 2008
The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross-sectional studyH G Raterman, I C van Eijk, A E Voskuyl, et al.
Rheumatology International|July 31, 2021
Cardiorespiratory fitness and physical activity in people who have rheumatoid arthritis at an increased risk of cardiovascular disease: a cross-sectional studyM Sobejana, J van den Hoek, G S Metsios, et al.
Scandinavian Journal of Rheumatology|March 2, 2022
Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trialJ Ruwaard, M J L' Ami, E L Kneepkens, et al.
Pageof 10